Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Cytopathology ; 34(4): 385-387, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-36967650

RESUMO

BACKGROUND: Dermal filler injections are being increasingly used as a non-surgical option for facial cosmetic procedures. However, their use has been implicated in multiple adverse events including immediate, early onset, and late onset complications. AIM: We present a case of dermal filler-induced foreign body reaction presenting as bilateral parotid lesions and diagnosed using fine needle aspiration. CONCLUSION: This case elucidate the risk of delayed adverse events in patients with dermal filler injections and stresses the importance of awareness by patients and providers for such events.


Assuntos
Preenchedores Dérmicos , Humanos , Preenchedores Dérmicos/efeitos adversos , Polimetil Metacrilato/efeitos adversos , Biópsia por Agulha Fina/efeitos adversos , Reação a Corpo Estranho/etiologia , Reação a Corpo Estranho/induzido quimicamente , Glândula Parótida/patologia
2.
Appl Immunohistochem Mol Morphol ; 31(2): 132-134, 2023 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-36730123

RESUMO

We describe our recent experience of studying expression of immunoglobulin (Ig) heavy chain (IgG, IgM, and IgA) in lymphoid cells comprising a research set of formalin-fixed, paraffin-embedded human diffuse large B-cell lymphoma samples. We found that using typical clinical automated immunohistochemistry protocols and usual buffers as blocking agents, the extent of undesirable staining was extreme and impaired our ability to interpret heavy chain Ig expression by individual lymphoid cells. We were not able to optimize this with serial dilutions in antibody concentration or time of primary antibody exposure. We therefore developed an added step of casein protein block, which solved the problem. We are not aware of other such reports in clinical or human research tissue sets and believe this solution may be useful when clinical pathologists or researchers encounter similar technical issues.


Assuntos
Cadeias Pesadas de Imunoglobulinas , Linfoma Difuso de Grandes Células B , Humanos , Caseínas , Imuno-Histoquímica , Linfócitos/patologia , Linfoma Difuso de Grandes Células B/patologia
3.
Leukemia ; 34(2): 553-566, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31570756

RESUMO

Regulating B-cell receptor (BCR) signaling after antigenic stimulation is essential to properly control immune responses. Currently known mechanisms of inhibiting BCR signaling are via co-receptor stimulation and downstream immunoreceptor tyrosine-based inhibition motif (ITIM) phosphorylation. Herein we demonstrate that BCR stimulation induces rapid and reversible palmitoylation of the SCF-FBXO10 ubiquitin E3 ligase. This results in FBXO10 relocation to the cell membrane, where it targets the human germinal center-associated lymphoma (HGAL) protein for ubiquitylation and degradation, leading to decreases in both BCR-induced calcium influx and phosphorylation of proximal BCR effectors. Importantly, FBXO10 recognition and degradation of HGAL is phosphorylation independent and instead relies on a single evolutionarily conserved HGAL amino acid residue (H91) and FBXO10 relocalization to the cytoplasmic membrane. Together our findings demonstrate the first evidence of negative BCR signaling regulation from direct BCR stimulation and define the temporospatial functions of the FBXO10-HGAL axis. FBXO10 is infrequently mutated in DLBCL but some of these mutations deregulate BCR signaling. These observations may have important implications on lymphomagenesis and other immune processes.


Assuntos
Proteínas F-Box/metabolismo , Centro Germinativo/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Proteínas dos Microfilamentos/metabolismo , Receptores de Antígenos de Linfócitos B/metabolismo , Linfócitos B/metabolismo , Membrana Celular/metabolismo , Humanos , Linfoma Difuso de Grandes Células B/metabolismo , Proteínas de Neoplasias/metabolismo , Fosforilação/fisiologia , Transdução de Sinais/fisiologia , Ubiquitina-Proteína Ligases/metabolismo
4.
Cancer Discov ; 9(7): 944-961, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31040105

RESUMO

The extraordinary activity of high-dose cyclophosphamide against some high-grade lymphomas was described nearly 60 years ago. Here we address mechanisms that mediate cyclophosphamide activity in bona fide human double-hit lymphoma. We show that antibody resistance within the bone marrow (BM) is not present upon early engraftment but develops during lymphoma progression. This resistance required a high tumor:macrophage ratio, was recapitulated in spleen by partial macrophage depletion, and was overcome by multiple, high-dose alkylating agents. Cyclophosphamide induced endoplasmic reticulum (ER) stress in BM-resident lymphoma cells in vivo that resulted in ATF4-mediated paracrine secretion of VEGFA, massive macrophage infiltration, and clearance of alemtuzumab-opsonized cells. BM macrophages isolated after cyclophosphamide treatment had increased phagocytic capacity that was reversed by VEGFA blockade or SYK inhibition. Single-cell RNA sequencing of these macrophages identified a "super-phagocytic" subset that expressed CD36/FCGR4. Together, these findings define a novel mechanism through which high-dose alkylating agents promote macrophage-dependent lymphoma clearance. SIGNIFICANCE: mAbs are effective against only a small subset of cancers. Herein, we recapitulate compartment-specific antibody resistance and define an ER stress-dependent mechanism induced by high-dose alkylating agents that promotes phagocytosis of opsonized tumor cells. This approach induces synergistic effects with mAbs and merits testing across additional tumor types.See related commentary by Duval and De Palma, p. 834.This article is highlighted in the In This Issue feature, p. 813.


Assuntos
Alemtuzumab/metabolismo , Alquilantes/administração & dosagem , Ciclofosfamida/administração & dosagem , Linfoma de Células B/tratamento farmacológico , Animais , Anticorpos Monoclonais/metabolismo , Medula Óssea/efeitos dos fármacos , Medula Óssea/metabolismo , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Humanos , Linfoma de Células B/metabolismo , Linfoma de Células B/patologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Distribuição Aleatória , Ensaios Antitumorais Modelo de Xenoenxerto
5.
Blood ; 132(19): 2026-2039, 2018 11 08.
Artigo em Inglês | MEDLINE | ID: mdl-30082494

RESUMO

The germinal center (GC) reaction plays an important role in generating humoral immunity and is believed to give rise to most B-cell lymphomas. GC entry and exit are tightly regulated processes, controlled by the actions of transcription factors such as BCL6. Herein, we demonstrate that protein arginine methyltransferase 5 (PRMT5), a symmetric dimethyl arginine methyltransferase, is also necessary for GC formation and affinity maturation. PRMT5 contributes to GC formation and affinity maturation at least in part through its direct interaction with and methylation of BCL6 at arginine 305 (R305), a modification necessary for the full transcriptional repressive effects of BCL6. Inhibition of PRMT5 in B-cell lymphoma lines led to significant upregulation of BCL6 target genes, and the concomitant inhibition of both BCL6 and PRMT5 exhibited synergistic killing of BCL6-expressing lymphoma cells. Our studies identify PRMT5 as a novel regulator of the GC reaction and highlight the mechanistic rationale of cotargeting PRMT5 and BCL6 in lymphoma.


Assuntos
Centro Germinativo/metabolismo , Linfoma/metabolismo , Mapas de Interação de Proteínas , Proteína-Arginina N-Metiltransferases/metabolismo , Proteínas Proto-Oncogênicas c-bcl-6/metabolismo , Animais , Linhagem Celular Tumoral , Proliferação de Células , Sobrevivência Celular , Regulação Neoplásica da Expressão Gênica , Centro Germinativo/citologia , Centro Germinativo/patologia , Humanos , Linfoma/genética , Linfoma/patologia , Camundongos Knockout , Proteína-Arginina N-Metiltransferases/genética , Proteínas Proto-Oncogênicas c-bcl-6/genética
6.
Sci Rep ; 6: 22760, 2016 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-26961797

RESUMO

Multiple myeloma is a plasma cell neoplasm with an extremely variable clinical course. Animal models are needed to better understand its pathophysiology and for preclinical testing of potential therapeutic agents. Hematopoietic cells expressing the hypermorphic Rad50(s) allele show hematopoietic failure, which can be mitigated by the lack of a transcription factor, Mef/Elf4. However, we find that 70% of Mef(-/-)Rad50(s/s) mice die from multiple myeloma or other plasma cell neoplasms. These mice initially show an abnormal plasma cell proliferation and monoclonal protein production, and then develop anemia and a decreased bone mineral density. Tumor cells can be serially transplanted and according to array CGH and whole exome sequencing, the pathogenesis of plasma cell neoplasms in these mice is not linked to activation of a specific oncogene, or inactivation of a specific tumor suppressor. This model recapitulates the systemic manifestations of human plasma cell neoplasms, and implicates cooperativity between the Rad50(s) and Mef/Elf4 pathways in initiating myelomagenic mutations that promote plasma cell transformation.


Assuntos
Transportadores de Cassetes de Ligação de ATP/genética , Proteínas de Ligação a DNA/genética , Mieloma Múltiplo/genética , Fenótipo , Fatores de Transcrição/genética , Hidrolases Anidrido Ácido , Animais , Células Sanguíneas/metabolismo , Células Sanguíneas/patologia , Células Sanguíneas/fisiologia , Células Sanguíneas/transplante , Densidade Óssea , Proliferação de Células , Células Cultivadas , Modelos Animais de Doenças , Exoma , Camundongos , Camundongos Endogâmicos C57BL , Mieloma Múltiplo/patologia
7.
Br J Haematol ; 165(5): 640-8, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24571259

RESUMO

Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.


Assuntos
Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Biomarcadores Tumorais/metabolismo , Neoplasias do Sistema Nervoso Central/diagnóstico , Proteínas de Ligação a DNA/metabolismo , Proteínas com Domínio LIM/metabolismo , Linfoma não Hodgkin/diagnóstico , Proteínas Proto-Oncogênicas/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Sistema Nervoso Central/tratamento farmacológico , Neoplasias do Sistema Nervoso Central/patologia , Humanos , Estimativa de Kaplan-Meier , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/patologia , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Proteínas de Neoplasias/metabolismo , Prognóstico , Proteínas Proto-Oncogênicas c-bcl-6 , Resultado do Tratamento
8.
Am J Hematol ; 88(9): 730-5, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23720088

RESUMO

The etiology and pathogenesis of ocular adnexal extranodal marginal zone lymphoma (OAEMZL) are still unknown and the association with Chlamydophila psittaci (C. psittaci) has been shown in only some geographic regions. Herein, we comprehensively examined the frequency of chromosomal translocations as well as CARD11, MYD88 (L265P), and A20 mutations/deletions in 45 C. psittaci negative OAEMZLs. t(14;18)(q32;q21) IGH-MALT1 and t(11;18)(q21;q21) API2-MALT1 were not detected in any of the analyzed tumors while three tumors harbored IGH translocations to an unidentified partner. CARD11 mutations were not found in all analyzed tumors, while the MYD88 L265P mutation was detected in three (6.7%) tumors. A20 mutations and deletions were each detected in seven (15.6%) and six (13.3%) tumors, respectively. Therefore, the observed genetic aberrations could account for the activation of the nuclear factor (NF)-kB signaling pathway in only a minority of the cases. Further studies are needed to identify the molecular mechanisms underlying the pathogenesis of OAEMZL.


Assuntos
Proteínas Adaptadoras de Sinalização CARD/genética , Proteínas de Ligação a DNA/genética , Neoplasias Oculares/genética , Guanilato Ciclase/genética , Peptídeos e Proteínas de Sinalização Intracelular/genética , Linfoma de Zona Marginal Tipo Células B/genética , Mutação , Fator 88 de Diferenciação Mieloide/genética , Proteínas de Neoplasias/genética , Proteínas Nucleares/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Sequência de Bases , Proteínas Adaptadoras de Sinalização CARD/metabolismo , Chlamydophila psittaci , Túnica Conjuntiva/metabolismo , Túnica Conjuntiva/patologia , Proteínas de Ligação a DNA/metabolismo , Neoplasias Oculares/metabolismo , Neoplasias Oculares/patologia , Feminino , Guanilato Ciclase/metabolismo , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Aparelho Lacrimal/metabolismo , Aparelho Lacrimal/patologia , Linfoma de Zona Marginal Tipo Células B/metabolismo , Linfoma de Zona Marginal Tipo Células B/patologia , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Fator 88 de Diferenciação Mieloide/metabolismo , Proteínas de Neoplasias/metabolismo , Proteínas Nucleares/metabolismo , Órbita/metabolismo , Órbita/patologia , Translocação Genética , Proteína 3 Induzida por Fator de Necrose Tumoral alfa
9.
Am J Hematol ; 88(5): 379-84, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23418012

RESUMO

Ocular adnexal mucosa associated lymphoid tissue lymphomas (OAMALTL) are the most common lymphomas of the eye. The potential roles for specific antigens in these lymphomas are still controversial. Previously we examined IGHV usage and mutations in Chlamydophila (C) psittaci-negative OAMALTL, demonstrating biased use of the IGHV4 family and IGHV4-34 gene and evidence for antigen selection. Herein, we examined the IGKV/IGLV gene usage and mutations in 34 C. psittaci-negative OAMALTL originating from the orbit (15), conjunctivae (14), and lacrimal gland (5). Clonal potentially functional IGKV/IGLV gene sequences were identified in 30 tumors (18 kappa and 12 lambda). An overrepresentation of the IGKV4 family (P < 0.01) was observed. The IGKV3-20*01 allele was used at a greater frequency than in normal peripheral blood B-lymphocytes (P = 0.02) and commonly paired with the IGHV4-34 allele. Twenty-seven of the 30 unique light chain sequences displayed mutations from germline and evidence for antigen selection. Overall our findings demonstrate that in C. psittaci-negative OAMALTL there is a biased usage of IGKV families and genes, which harbor somatic mutations. These findings and the specific paring between the IGKV3-20*01 and IGHV4-34 alleles suggest that specific antigens could play an important role in the pathogenesis of these lymphomas.


Assuntos
Neoplasias Oculares/genética , Região Variável de Imunoglobulina/genética , Cadeias kappa de Imunoglobulina/genética , Cadeias lambda de Imunoglobulina/genética , Linfoma/genética , Proteínas de Neoplasias/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia , Células Clonais/metabolismo , Estudos de Coortes , Neoplasias da Túnica Conjuntiva/genética , Neoplasias da Túnica Conjuntiva/metabolismo , Neoplasias da Túnica Conjuntiva/patologia , Neoplasias Oculares/metabolismo , Neoplasias Oculares/patologia , Feminino , Estudos de Associação Genética , Humanos , Região Variável de Imunoglobulina/metabolismo , Cadeias kappa de Imunoglobulina/metabolismo , Cadeias lambda de Imunoglobulina/metabolismo , Doenças do Aparelho Lacrimal/genética , Doenças do Aparelho Lacrimal/metabolismo , Doenças do Aparelho Lacrimal/patologia , Tecido Linfoide/metabolismo , Linfoma/metabolismo , Linfoma/patologia , Masculino , Pessoa de Meia-Idade , Mutação , Proteínas de Neoplasias/metabolismo , Neoplasias Orbitárias/genética , Neoplasias Orbitárias/metabolismo , Neoplasias Orbitárias/patologia
10.
Blood ; 120(20): 4182-90, 2012 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-23024238

RESUMO

Follicular lymphoma is a monoclonal B-cell malignancy with each patient's tumor expressing a unique cell surface immunoglobulin (Ig), or B-cell receptor (BCR), that can potentially recognize antigens and/or transduce signals into the tumor cell. Here we evaluated the reactivity of tumor derived Igs for human tissue antigens. Self-reactivity was observed in 26% of tumor Igs (25 of 98). For one follicular lymphoma patient, the recognized self-antigen was identified as myoferlin. This patient's tumor cells bound recombinant myoferlin in proportion to their level of BCR expression, and the binding to myoferlin was preserved despite ongoing somatic hypermutation of Ig variable regions. Furthermore, BCR-mediated signaling was induced after culture of tumor cells with myoferlin. These results suggest that antigen stimulation may provide survival signals to tumor cells and that there is a selective pressure to preserve antigen recognition as the tumor evolves.


Assuntos
Autoantígenos/imunologia , Proteínas de Ligação ao Cálcio/imunologia , Linfoma Folicular/imunologia , Proteínas de Membrana/imunologia , Proteínas Musculares/imunologia , Proteínas de Neoplasias/imunologia , Receptores de Antígenos de Linfócitos B/imunologia , Anticorpos Antineoplásicos/química , Anticorpos Antineoplásicos/genética , Anticorpos Antineoplásicos/imunologia , Autoantígenos/genética , Autoimunidade , Proteínas de Ligação ao Cálcio/genética , Linhagem Celular Tumoral , Sobrevivência Celular , DNA de Neoplasias/genética , Glicosilação , Humanos , Imunoglobulina G/química , Imunoglobulina G/genética , Imunoglobulina G/imunologia , Cadeias Pesadas de Imunoglobulinas/genética , Cadeias Leves de Imunoglobulina/genética , Interferometria , Proteínas de Membrana/genética , Proteínas Musculares/genética , Proteínas de Neoplasias/genética , Processamento de Proteína Pós-Traducional , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Proteínas Quinases S6 Ribossômicas 90-kDa/metabolismo , Microambiente Tumoral/imunologia
11.
Leuk Lymphoma ; 52(12): 2254-61, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21740306

RESUMO

The incidence of patients with multiple primary tumors has been increasing in recent years. The association between non-Hodgkin lymphomas (NHL) and renal cell carcinoma (RCC) is unclear. The presentation of 10 patients with co-existent NHL and RCC at our institution in the past 3 years led us to explore whether this was a chance association or a statistically significant phenomenon. We used the US Surveillance, Epidemiology and End Results (SEER) program (www.seer.cancer.gov) from 1973 to 2006 to identify a total of 892 445 537 subjects aged 18-84, with known values for race and gender at risk for NHL and RCC. Among these, 181 009 were diagnosed with NHL, 118 122 were diagnosed with RCC and 1039 had both NHL and RCC. This was significantly higher than the expected number of 24 with co-existent NHL and RCC (p < 0.0001). The observed number (O) of RCC after NHL was significantly higher than the expected number (E) (O/E: 1.51; 95% confidence interval [CI] 1.36-1.66), with the O/E ratio remaining elevated across the various follow-up time intervals. The observed number of NHL after RCC was not significantly different from the expected number (O/E: 1.09; 95% CI 0.98-1.22). In univariate analyses, race and gender were significantly associated with an increased cumulative incidence of RCC after NHL. Multivariate analysis with age, race and gender revealed that white males had a higher cumulative incidence of RCC after NHL. These findings suggest that patients with NHL are at increased risk for RCC.


Assuntos
Carcinoma de Células Renais/epidemiologia , Linfoma não Hodgkin/epidemiologia , Neoplasias Primárias Múltiplas/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Programa de SEER , Adulto Jovem
12.
PLoS One ; 6(12): e29114, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22216179

RESUMO

Extranodal marginal zone lymphomas (EMZL) are the most common lymphomas in the ocular adnexa. The etiology and potential role for antigenic stimulation in these lymphomas are still controversial. We have examined IGHV gene usage and mutations in 67 Chlamydophila psittaci-negative ocular adnexal EMZL. Clonal IGHV gene sequences were identified in 43 tumors originating from the orbit (19), conjunctivae (18) and lacrimal gland (6). Forty four potentially functional clonal IGHV gene sequences were detected with overrepresentation of the IGHV4 family and IGHV4-34 gene. All but 3 sequences were mutated with the average percent homology to the germ line of 93.5±6.1. Multinomial model and Focused binomial test demonstrated evidence for positive and/or negative antigen selection in 59% of the potentially functional IGHV genes. Intraclonal variation was detected in 8 of 11 tumor specimens. Overall our findings demonstrate that C. psittaci-negative ocular adnexal EMZL exhibit biased usage of IGHV families and genes with evidence for intraclonal heterogeneity and antigen selection in multiple tumors, implicating B-cell receptor-mediated antigen stimulation in the pathogenesis of these lymphomas.


Assuntos
Antígenos de Bactérias/imunologia , Chlamydophila psittaci/imunologia , Neoplasias Oculares/microbiologia , Cadeias Pesadas de Imunoglobulinas/genética , Linfoma de Zona Marginal Tipo Células B/microbiologia , Humanos , Dados de Sequência Molecular , Mutação
13.
Leuk Lymphoma ; 51(7): 1200-16, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20370541

RESUMO

Adult T-cell leukemia-lymphoma (ATLL) is an HTLV-1-associated lymphoproliferative malignancy that is frequently fatal. We compared gene expression profiles (GEPs) of leukemic specimens from nine patients with ATLL at the time of diagnosis and immediately after combination therapy with zidovudine (AZT) and interferon alpha (IFNalpha). GEPs were also related to genetic aberrations determined by comparative genomic hybridization. We identified several genes anomalously over-expressed in the ATLL leukemic cells at the mRNA level, including LYN, CSPG2, and LMO2, and confirmed LMO2 expression in ATLL cells at the protein level. In vivo AZT-IFNalpha therapy evoked a marked induction of interferon-induced genes accompanied by repression of cell-cycle regulated genes, including those encoding ribosomal proteins. Remarkably, patients not responding to AZT-IFNalpha differed most from responding patients in lower expression of these same IFN-responsive genes, as well as components of the antigen processing and presentation apparatus. Demonstration of specific gene expression signatures associated with response to AZT-IFNalpha therapy may provide novel insights into the mechanisms of action in ATLL.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Biomarcadores Tumorais/genética , Perfilação da Expressão Gênica , Interferon-alfa/uso terapêutico , Leucemia-Linfoma de Células T do Adulto/tratamento farmacológico , Leucemia-Linfoma de Células T do Adulto/genética , Zidovudina/uso terapêutico , Adulto , Biomarcadores Tumorais/metabolismo , Hibridização Genômica Comparativa , Quimioterapia Combinada , Humanos , Leucemia-Linfoma de Células T do Adulto/patologia , Análise de Sequência com Séries de Oligonucleotídeos , RNA Mensageiro/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA